

PAROXETINE CONTROLLED RELEASE COMPOSITIONS

Chs 91

The present invention relates to a novel formulation containing paroxetine or a pharmaceutically acceptable salt thereof, and to its use in the treatment 5 and/or prophylaxis of certain disorders.

US Patent No 4,007,196 describes *inter alia* a compound which is commonly known as paroxetine. This compound is a Selective Serotonin Reuptake Inhibitor (SSRI) and is currently marketed world-wide for the treatment and/or prophylaxis of depression.

10 The current formulation which is the only marketed formulation of paroxetine hydrochloride is a swallow tablet.

It has now been surprisingly found that controlled release and delayed release formulations containing paroxetine give rise to an unexpected reduction in the side effects associated with swallow tablets.

15 Accordingly, the present invention provides a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof.

20 A further aspect of the invention provides a controlled release or delayed release formulation containing an SSRI. Examples of SSRIs other than paroxetine include fluoxetine (US Patent No. 4,314,081), fluvoxamine (US Patent No. 4,085,225), and sertraline (US Patent No. 4,536,518).

25 By controlled release is meant any formulation technique wherein release of the active substance from the dosage form is modified to occur at a slower rate than that from an immediate release product, such as a conventional swallow tablet or capsule.

30 By delayed release is meant any formulation technique wherein release of the active substance from the dosage form is modified to occur at a later time than that from a conventional immediate release product. The subsequent release of active substance from a delayed release formulation may also be controlled as defined above.

Examples of controlled release formulations which are suitable for incorporating paroxetine and other SSRIs are described in:

Sustained Release Medications, Chemical Technology Review No. 177.

Ed. J.C. Johnson. Noyes Data Corporation 1980.

35 Controlled Drug Delivery, Fundamentals and Applications, 2nd Edition.
Eds. J.R. Robinson, V.H.L. Lee. Marcel Dekker Inc. New York 1987.

Examples of delayed release formulations which are suitable for incorporating paroxetine and other SSRIs are described in:

Remington's Pharmaceutical Sciences 16th Edition, Mack Publishing Company 1980, Ed. A. Osol.

5 Such controlled release formulations are preferably formulated in a manner such that release of active substance such as paroxetine is effected predominantly during the passage through the stomach and the small intestine, and delayed release formulations are preferably formulated such that release of active substance such as paroxetine is avoided in the stomach and is effected
10 predominantly during passage through the small intestine.

Said formulations are preferably formulated such that the release of the active substance is predominantly 1½ to 3 hours post ingestion.

The small intestine is suitably the duodenum, the ileum or the jejunum.

15 Patients who benefit most from the formulations of the present invention are those who are known to suffer from nausea upon oral administration using swallow tablets.

Preferred formulations are ultimately enteric coated tablets or caplets, wax or polymer coated tablets or caplets or time-release matrices, or combinations thereof.

20 Particularly preferred formulations are described in US Patent No.

5,102,666.

Thus, a particular aspect of the invention provides a polymeric controlled release composition comprising a reaction complex formed by the interaction of (1) a calcium polycarbophil component which is a water-swellable, but water
25 insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80% contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerised repeating unit and cross-linking agent,
30 respectively, with (2) water, in the presence of an active agent selected from the group consisting of SSRIs such as paroxetine. The amount of calcium polycarbophil present is from about 0.1 to about 99% by weight, for example about 10%. The amount of active agent present is from about 0.0001 to about 65% by weight, for example between about 5 and 20%. The amount of water present is from about 5 to about 200% by weight, for example between about 5 and 10%. The interaction is carried out at a pH of between about 3 and about 10.

for example about 6 to 7. The calcium polycarbophil is originally present in the form of a calcium salt containing from about 5 to about 25% calcium.

Further particularly preferred formulations are described in US Patent No. 5,422,123.

5 Thus, a further particular aspect of the invention provides a system for the controlled release of an active substance which is an SSRI such as paroxetine, comprising (a) a deposit-core comprising an effective amount of the active substance and having defined geometric form, and (b) a support-platform applied to said deposit-core, wherein said deposit-core contains at least the active
10 substance, and at least one member selected from the group consisting of (1) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the said swellable polymeric material to said gellable polymeric material is in the range 1:9 to 9:1, and (2) a single polymeric material having both swelling and gelling properties, and
15 wherein the support-platform is an elastic support, applied to said deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids. The support-platform may comprise polymers such as hydroxypropylmethylcellulose, plasticizers such as a glyceride, binders such as
20 polyvinylpyrrolidone, hydrophilic agents such as lactose and silica, and/or hydrophobic agents such as magnesium stearate and glycerides. The polymer(s) typically make up 30 to 90% by weight of the support-platform, for example about 35 to 40%. Plasticizer may make up at least 2% by weight of the support-platform, for example about 15 to 20%. Binder(s), hydrophilic agent(s) and
25 hydrophobic agent(s) typically total up to about 50% by weight of the support-platform, for example about 40 to 50%.

Paroxetine used in the present invention is suitably in the form of the free base or a pharmaceutically acceptable salt thereof. Preferably, paroxetine is suitably in the form of the hydrochloride hemihydrate.

30 Paroxetine hydrochloride hemihydrate may be prepared according to the procedures generally outlined in US Patent 4,721,723..

Paroxetine in the form of a controlled release or delayed release formulation can be used to treat and prevent the following disorders:

35 Alcoholism
 - Anxiety
 - Depression

Obsessive Compulsive Disorder
Panic Disorder
Chronic Pain
Obesity
5 Senile Dementia
Migraine
✓ Bulimia
✓ Anorexia
Social Phobia
10 Pre-Menstrual Syndrome (PMS)
Adolescent Depression
Trichotillomania
Dysthymia
Substance Abuse
15

These disorders are herein after referred to as "the disorders".
The present invention provides a method of treating and/or preventing the disorders by administering an effective and/or a prophylactic amount of a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof, to a sufferer in need thereof.

The present invention further provides the use of a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament, for treating and/or preventing the disorders.

The present invention also provides a pharmaceutical composition for use in the treatment and/or prevention of the disorders which comprises a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof.

The following examples illustrate the present invention.

30 Example 1 (Hydrophilic Matrix)

	Intrgranular	<u>% w/w</u>
	Paroxetine Hydrochloride	11.45
35	Methocel E5	1.25
	Lactose	12.3
	Extrgranular	
	Methocel K100LV	30.0

Lactose	44.0
Magnesium Stearate	1.0
TOTAL	100.0

5 **Example 2** (Hydrophilic Matrix)

	Intragranular	<u>% w/w</u>
	Paroxetine Hydrochloride	11.45
	Methocel E5	1.25
10	Lactose	12.3
	Extragranular	
	Methocel K100LV	27.5
	Methocel K4M	7.5
	Lactose	39.0
15	Magnesium Stearate	1.0
	TOTAL	100.0

Example 3 (pH Sensitive Coat on Immediate Release Core)

20	Tablet Core	<u>%w/w</u>
	Paroxetine Hydrochloride	11.45
	Lactose	64.05
	Microcrystalline Cellulose	20.0
	Sodium Starch Glycollate	4.0
25	Magnesium Stearate	0.5
	TOTAL	100.0

	Tablet Coating (apply approximately 6-10% of tablet core weight)	<u>%w/w</u>
	Hydroxypropylmethylcellulose Phthalate	90.0
30	Triacetin	10.0

Example 4 (pH Sensitive Coat on Immediate Release Core)

Tablet Core as in Example 3

35	Tablet Coating (apply approximately 6-10% of tablet core weight)	<u>%w/w</u>
----	--	--------------------

Cellulose Acetate Phthalate	90.0
Diethyl Phthalate	10.0

Example 5 (Controlled Release Coating on Immediate Release Core)

5

Tablet Core as in Example 3

Tablet Coating (apply approximately 5-12% of tablet core weight)		<u>%w/w</u>
	Eudragit RS 100	86.0
10	Dibutyl Phthalate	10.0
	Talc	4.0
	FD&C Yellow No. 6	0.01

Example 6 (pH Sensitive Coat on Controlled Release Core.)

15

Tablet Core as in Example 3**Tablet Coating as in Example 3****20 Example 7 (Encapsulated Controlled Release Coated Beads)**

Pellet	<u>%w/w (approx)</u>
--------	----------------------

Non Pareil Seed	30
Paroxetine Hydrochloride	40
25 Gelatin	8
Lactose	20
Talc	2

Coating	<u>%w/w</u>
---------	-------------

30	Glycerylmonostearate	36.6
	Glyceryldistearate	53.4
	White Wax	10.0

Example 8 (Controlled release bilayer tablet)**Active Layer**

5

	Component	mg/tablet	Function
	Paroxetine Hydrochloride	22.89*	Active
	Methocel K4M	15.00	Hydrogel polymer
	Lactose monohydrate	62.0	Hydrophilic agent
10	Polyvinylpyrrolidone	3.0	Binder
	Magnesium stearate	1.0	Hydrophobic agent
	Syloid 244	1.0	Hydrophilic agent

Support platform

15

	Component	mg/tablet	Function
	Compritol 888	15.04	Plasticizer
	Lactose monohydrate	29.32	Hydrophilic agent
20	Polyvinylpyrrolidone	4.0	Binder
	Magnesium stearate	1.52	Hydrophobic agent
	Methocel E5	29.32	Hydrogel polymer
	Iron oxide	0.08	Colourant
25	Total tablet weight	184.89mg	

*Equivalent to 20mg paroxetine as free base.

The powder blend for each layer was wet granulated in a high shear

30 mixer/granulator and dried in a fluid bed drier. The bilayer tablets were compressed on a Manesty triple layer press.

Example 9 (Enteric coated calcium polycarbophil formulation)**Core**

	Component	mg/tablet	Function
5	Paroxetine Hydrochloride	22.89*	Active
	Calcium polycarbophil	20.00	Matrix
	Lactose anhydrous	146.11	Hydrophilic agent/diluent
	Polyvinylpyrrolidone	10.0	Binder
10	Magnesium stearate	1.0	Hydrophobic agent/lubricant
	Water**	0.024	Granulating liquid

Enteric coat

	Component	mg/tablet	Function
15	Eudragit	22.19	Polymer
	Talc	1.53	Lubricant
	Triethyl citrate	1.00	Plasticizer
20	Water**	24.6	Diluent

Film coat

25	Opadry pink	10.5	Film coat
	Water**	94.5	Diluent

Polish coat

30	Opadry clear	0.750	
	Water**	29.3	Diluent

*Equivalent to 20mg paroxetine as free base.

**Removed during processing.

35 The core constituents were wet granulated in a high shear mixer/granulator, and dried in a fluid bed drier. The magnesium stearate was then added and the

mixture processed in a low shear mixer. The mix was then compressed on a B type rotary tablet press. Coating was carried out using an Accela cota.

Example 10 (Controlled release bilayer tablet)

5

Active Layer

	Component	mg/tablet	Function
	Paroxetine Hydrochloride	22.89*	Active
10	Methocel K4M	20.00	Hydrogel polymer
	Lactose monohydrate	60.0	Hydrophilic agent
	Polyvinylpyrrolidone	5.0	Binder
	Magnesium stearate	1.0	Hydrophobic agent
	Syloid 244	1.0	Hydrophilic agent

15

Support platform

	Component	mg/tablet	Function
20	Compritol 888	14.72	Plasticizer
	Lactose monohydrate	30.60	Hydrophilic agent
	Polyvinylpyrrolidone	2.80	Binder
	Magnesium stearate	0.80	Hydrophobic agent
	Methocel E5	30.60	Hydrogel polymer
25	Syloid 244	0.40	Hydrophilic agent
	Iron oxide	0.08	Colourant

Total tablet weight 189.89mg

30 *Equivalent to 20mg paroxetine as free base.

The process was as described in Example 8.

Example 11 (Controlled release bilayer tablet)

Active Layer

5	Component	mg/tablet	Function
	Paroxetine Hydrochloride	22.89*	Active
	Methocel K4M	15.00	Hydrogel polymer
	Lactose monohydrate	63.31	Hydrophilic agent
	Polyvinylpyrrolidone	2.0	Binder
10	Magnesium stearate	1.0	Hydrophobic agent
	Syloid 244	0.40	Hydrophilic agent

Support platform - as in Example 10.

15 Total tablet weight 184.60mg

*Equivalent to 20mg paroxetine as free base.

The process was as described in Example 8.

20

Active Layer

25	Component	mg/tablet	Function
	Paroxetine Hydrochloride	28.61*	Active
	Methocel K4M	18.75	Hydrogel polymer
	Lactose monohydrate	79.14	Hydrophilic agent
	Polyvinylpyrrolidone	2.50	Binder
30	Magnesium stearate	1.25	Hydrophobic agent
	Syloid 244	0.50	Hydrophilic agent

Support platform

	Component	mg/tablet	Function
5	Compritol 888	15.04	Plasticizer
	Lactose monohydrate	30.50	Hydrophilic agent
	Polyvinylpyrrolidone	4.00	Binder
	Magnesium stearate	0.80	Hydrophobic agent
	Methocel E5	29.32	Hydrogel polymer
10	Sylloid 244	0.32	Hydrophilic agent
	Iron oxide	0.02	Colourant

Enteric coating

	Component	mg/tablet	Function
	Eudragit	13.27	Polymer
	Talc	3.31	Lubricant
	Triethyl citrate	1.33	Plasticizer
20	Water**	36.25	Diluent
	Total tablet weight	228.66mg	

*Equivalent to 25mg paroxetine as free base.

25

**Removed during processing.

The process was as described in Example 9.

Example 13

GI tolerance study

The design of the study is outlined below

5	Subjects:	Normal healthy volunteers
	Design:	Parallel group, placebo controlled, double blind
	Treatment:	(a) Placebo, (b) Immediate release paroxetine, (c)Example 8 formulation, (d) Example 8 formulation with enteric coating.
10	Dosage:	30 mg once daily for 3 days
	Number of subjects:	452 evaluable (488 randomised, 485 evaluable)

The study was conducted to compare the incidence, severity and duration of nausea and vomiting, and diarrhoea (theoretically if the controlled release

15 formulations slow down absorption of paroxetine then, as paroxetine is known to be prokinetic to the GI tract there may be an increased incidence).

Adverse experiences (AE) information was assessed each morning at the time of dosing and again 24 hours following the last dose. Investigators and subjects

20 were given diary cards detailing how to classify severity of AEs in order to standardise as much as possible across all 6 centres.

Of the 485 evaluable subjects, 18 (3.7%) withdrew, 17 because of adverse events.

Subjects with nausea/vomiting on the day of withdrawal were more common on

25 (b) than either of (c) and (d)

The incidence of nausea/vomiting and diarrhoea is shown in the table below:

	(b)	(c)	(d)	Placebo
Incidence of nausea	59%	49%	39%	13%
Incidence of diarrhoea	15%	21%	20%	7%

30 The incidence of nausea was increased for both (b) and placebo compared to the expected rates of approximately 25% and 5% respectively for volunteers at these dosages for 3 days duration. The overall incidence of nausea was less on (c) and

(d) than on (b). The severity of nausea was also decreased as shown in the next table.

Nausea severity	(b)	(c)	(d)	Placebo
None	50 (41%)	63 (52%)	74 (61%)	104 (87%)
Mild	45 (37%)	40 (33%)	30 (25%)	16 (13%)
Moderate	21 (17%)	17 (14%)	15 (12%)	0 (0%)
Severe	6 (5%)	1 (1%)	3 (2%)	0 (0%)

5 Severity of diarrhoea is reported in the table below:

Severity of diarrhoea	(b)	(c)	(d)	Placebo
None	104 (85%)	95 (79%)	97 (80%)	112 (93%)
Mild	16 (13%)	16 (13%)	16 (13%)	8 (7%)
Moderate	1 (1%)	8 (7%)	9 (7%)	0 (0%)
Severe	1 (1%)	2 (2%)	0 (0%)	0 (0%)

In conclusion, there appears to be a trend for (c) to reduce the incidence of nausea and the dropout rate due to adverse events in comparison to (b), but analysis of 10 the results was complicated by a statistically significant treatment-by-centre difference. (d) shows a halving in the dropout rate and a fall in incidence of nausea of 20% (a proportional fall of 33%). In addition there is a reduction in severity of nausea of those individuals who report nausea on (c) and (d). There is an increase in incidence of diarrhoea on both of (c) and (d) in relation to (b), but 15 this is confined to an increase in the number of individuals reporting moderate diarrhoea and there is no increase in those with severe diarrhoea.